Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials

Methods in Molecular Biology

Volumn 1693, Issue , 2018, Pages 159-170

  Fish, Randolph ^a,b   Kutter, Elizabeth ^a,c   Wheat, Gordon ^a,d   Blasdel, Bob ^e   Kutateladze, Mzia ^f   Kuhl, Sarah ^g,h  

^a Grays Harbor Community Hospital   (United States)

^b Ambulatory Care Center   (United States)

^c EVERGREEN STATE COLLEGE   (United States)

^d KAISER PERMANENTE   (United States)

^e LABORATORY OF GENE TECHNOLOGY   (Belgium)

^f Laboratory of Genetic Engineering and Biotechnology   (United States)

^g VA Northern California Healthcare System   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amputation; Bacteriophage therapy; Debridement; Diabetic foot ulcers; Osteomyelitis

Indexed keywords

ANTIBIOTIC AGENT; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; AGED; ANKLE EDEMA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTIFICIAL EMBOLIZATION; BACTERIOPHAGE; BACTERIUM CULTURE; CASE REPORT; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; COMPASSIONATE USE; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FOOT AMPUTATION; FOOT ULCER; GANGRENE; HALLUX; HUMAN; HYPERLIPIDEMIA; MALE; MEDICAL HISTORY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOMYELITIS; PATIENT SAFETY; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHAGE THERAPY; PLETHYSMOGRAPHY; PROXIMAL PHALANX; SKIN ULCER; SOFT TISSUE INFECTION; STAPHYLOCOCCUS EPIDERMIDIS; THERAPY EFFECT; TOE; WOUND HEALING; WOUND INFECTION; BACTERIAL INFECTION; BACTERIAL PHENOMENA AND FUNCTIONS; COMPLICATION; MICROBIOLOGY;

BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BACTERIOPHAGES; FOOT ULCER; HUMANS; PHAGE THERAPY;

EID: 85033665691     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-7395-8_14     Document Type: Chapter

References (21)

1. Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, Johnston MD, Barton HA, Wright GD (2012) Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One 7:e34953. doi:10.1371/journal. pone.0034953
2. D’Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D et al (2011) Antibiotic resistance is ancient. Nature 477:457–461. doi:10.1038/nature10388
3. Boyko EJ, Lipsky BA (1995) Infection and diabetes mellitus. In: Harris I (ed) Diabetes in America, 2nd edn. NIH, Washington, DC, pp 485–496
4. Oates A, Bowling FL, Boulton AJ, McBain AJ (2012) A molecular and culture-based assessment of the microbial diversity of the diabetic chronic foot wounds and contralateral skin sites. J Clin Microbiol 50:2263–2271
5. Abularrage CJ, Sidawy AN, Aidinian G, Singh N, Weiswasser JM, Arora S (2005) Evaluation of the microcirculation in vascular disease. J Vasc Surg. doi:10.1016/j.jvs.2005.05. 019
6. Game F (2010) Management of osteomyelitis of the foot in diabetes mellitus. Nat Rev Endo-crinol 6:43–47. doi:10.1038/nrendo.2009. 243
7. Lázaro-Martínez JL, Aragón-Sánchez J, Gar-cía-Morales E (2014) Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. Diabetes Care 37:789–795. doi:10.2337/dc13-1526
8. Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S (2016) Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 25:S27–S33. doi:10. 12968/jowc.2016.25.7.S27
9. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG et al (2012) Infectious diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54:132–173. doi:10.1093/cid/cis346
10. Scheck M (1977) Etiology of acquired ham-mertoe deformity. Clin Orthop Relat Res 123:63–69
11. Barfoed BL, Paulsen MS, Christensen PM, Halvorsen PA, Jarbøl DE, Larsen ML, Munch MR, Søndergaard J, Nielsen JB (2016) Associations between patients’ adherence and GPs’ attitudes towards risk, statin therapy and management of non-adherence-a survey and register-based study. Fam Pract 33:140–147. doi:10.1093/fampra/cmw005
12. Kvachadze L, Balarjishvili N, Meskhi T, Tevdoradze E, Skhirtladze N, Pataridze T, Adamia R et al (2011) Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 4:643–650. doi:10.1111/j.1751-7915.2011.00259.x
13. Kutateladze M, Adamia R (2008) Phage therapy experience at the Eliava Institute. Med Malad Infect 38:426–430. doi:10.1016/j. medmal.2008.06.023
14. Kutateladze M, Adamia R (2010) Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28:591–595. doi:10.1016/j.tibtech.2010.08. 001
15. Tevdoradze E, Kvachadze L, Kutateladze M, Stewart CR (2014) Bactericidal genes of staphylococcal bacteriophage Sb-1. Curr Microbiol 68:204–210. doi:10.1007/s00284-013-0456-9
16. Wolcott RD, Rhoads DD, Dowd SE (2008) Biofilms and chronic wound inflammation. J Wound Care 17:333–341. doi:10.12968/jowc.2008.17.8.30796
17. Granger DN, E Senchenkova. 2010. Inflammation and the microcirculation. Colloquium series on integrated systems physiology: from molecule to function, vol 2. doi:10.4199/C00013ED1V01Y201006ISP008
18. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treatment of human infections. Bacteriophage 1:66–85. doi:10.4161/bact.1. 2.15845
19. Chanishvili N (2016) Bacteriophages as therapeutic and prophylactic means: summary of the Soviet and post Soviet experiences. Curr Drug Deliv 13(3):309–323
20. Górski A, Międzybrodzki R, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Rogóż P, Jończyk-Matysiak E, Dąbrowska K, Majewska J, Borysowski J (2016) Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol 7:1515. doi:10.3389/fmicb.2016.01515
21. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A (2009) Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:237–243. doi:10.12968/jowc.2009.18.6.42801